BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 34153521)

  • 1. Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis.
    Serrano-Maciá M; Simón J; González-Rellan MJ; Azkargorta M; Goikoetxea-Usandizaga N; Lopitz-Otsoa F; De Urturi DS; Rodríguez-Agudo R; Lachiondo-Ortega S; Mercado-Gomez M; Gutiérrez de Juan V; Bizkarguenaga M; Fernández-Ramos D; Buque X; Baselli GA; Valenti LVC; Iruzubieta P; Crespo J; Villa E; Banales JM; Avila MA; Marin JJG; Aspichueta P; Sutherland J; Barrio R; Mayor U; Elortza F; Xirodimas DP; Nogueiras R; Delgado TC; Martínez-Chantar ML
    Mol Metab; 2021 Nov; 53():101275. PubMed ID: 34153521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease.
    Majdi A; Aoudjehane L; Ratziu V; Islam T; Afonso MB; Conti F; Mestiri T; Lagouge M; Foufelle F; Ballenghien F; Ledent T; Moldes M; Cadoret A; Fouassier L; Delaunay JL; Aït-Slimane T; Courtois G; Fève B; Scatton O; Prip-Buus C; Rodrigues CMP; Housset C; Gautheron J
    J Hepatol; 2020 Apr; 72(4):627-635. PubMed ID: 31760070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DEP domain-containing mTOR-interacting protein suppresses lipogenesis and ameliorates hepatic steatosis and acute-on-chronic liver injury in alcoholic liver disease.
    Chen H; Shen F; Sherban A; Nocon A; Li Y; Wang H; Xu MJ; Rui X; Han J; Jiang B; Lee D; Li N; Keyhani-Nejad F; Fan JG; Liu F; Kamat A; Musi N; Guarente L; Pacher P; Gao B; Zang M
    Hepatology; 2018 Aug; 68(2):496-514. PubMed ID: 29457836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Schisandrin B mitigates hepatic steatosis and promotes fatty acid oxidation by inducing autophagy through AMPK/mTOR signaling pathway.
    Yan LS; Zhang SF; Luo G; Cheng BC; Zhang C; Wang YW; Qiu XY; Zhou XH; Wang QG; Song XL; Pan SY; Zhang Y
    Metabolism; 2022 Jun; 131():155200. PubMed ID: 35405150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kangtaizhi Granule Alleviated Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Rats and HepG2 Cells via AMPK/mTOR Signaling Pathway.
    Zhang J; Du H; Shen M; Zhao Z; Ye X
    J Immunol Res; 2020; 2020():3413186. PubMed ID: 32884949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation.
    Castaño D; Larequi E; Belza I; Astudillo AM; Martínez-Ansó E; Balsinde J; Argemi J; Aragon T; Moreno-Aliaga MJ; Muntane J; Prieto J; Bustos M
    J Hepatol; 2014 May; 60(5):1017-25. PubMed ID: 24362075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fisetin Protects Against Hepatic Steatosis Through Regulation of the Sirt1/AMPK and Fatty Acid β-Oxidation Signaling Pathway in High-Fat Diet-Induced Obese Mice.
    Liou CJ; Wei CH; Chen YL; Cheng CY; Wang CL; Huang WC
    Cell Physiol Biochem; 2018; 49(5):1870-1884. PubMed ID: 30235452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of neddylation regulates dendritic cell functions via Deptor accumulation driven mTOR inactivation.
    Cheng M; Hu S; Wang Z; Pei Y; Fan R; Liu X; Wang L; Zhou J; Zheng S; Zhang T; Lin Y; Zhang M; Tao R; Zhong J
    Oncotarget; 2016 Jun; 7(24):35643-35654. PubMed ID: 27224922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease.
    Cansby E; Nuñez-Durán E; Magnusson E; Amrutkar M; Booten SL; Kulkarni NM; Svensson LT; Borén J; Marschall HU; Aghajan M; Mahlapuu M
    Cell Mol Gastroenterol Hepatol; 2019; 7(3):597-618. PubMed ID: 30576769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MLN4924 Treatment Diminishes Excessive Lipid Storage in High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease (NAFLD) by Stimulating Hepatic Mitochondrial Fatty Acid Oxidation and Lipid Metabolites.
    Ge M; Huang L; Ma Y; Sun S; Wu L; Xu W; Yang D
    Pharmaceutics; 2022 Nov; 14(11):. PubMed ID: 36432651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of hepassocin in the development of non-alcoholic fatty liver disease.
    Wu HT; Lu FH; Ou HY; Su YC; Hung HC; Wu JS; Yang YC; Wu CL; Chang CJ
    J Hepatol; 2013 Nov; 59(5):1065-72. PubMed ID: 23792031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OXPHOS-Mediated Induction of NAD+ Promotes Complete Oxidation of Fatty Acids and Interdicts Non-Alcoholic Fatty Liver Disease.
    Akie TE; Liu L; Nam M; Lei S; Cooper MP
    PLoS One; 2015; 10(5):e0125617. PubMed ID: 25933096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hesperetin ameliorates hepatic oxidative stress and inflammation
    Li J; Wang T; Liu P; Yang F; Wang X; Zheng W; Sun W
    Food Funct; 2021 May; 12(9):3898-3918. PubMed ID: 33977953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toyocamycin attenuates free fatty acid-induced hepatic steatosis and apoptosis in cultured hepatocytes and ameliorates nonalcoholic fatty liver disease in mice.
    Takahara I; Akazawa Y; Tabuchi M; Matsuda K; Miyaaki H; Kido Y; Kanda Y; Taura N; Ohnita K; Takeshima F; Sakai Y; Eguchi S; Nakashima M; Nakao K
    PLoS One; 2017; 12(3):e0170591. PubMed ID: 28278289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone Morphogenetic Protein-8B Expression is Induced in Steatotic Hepatocytes and Promotes Hepatic Steatosis and Inflammation In Vitro.
    Mahli A; Seitz T; Beckröge T; Freese K; Thasler WE; Benkert M; Dietrich P; Weiskirchen R; Bosserhoff A; Hellerbrand C
    Cells; 2019 May; 8(5):. PubMed ID: 31096638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensinogen in hepatocytes contributes to Western diet-induced liver steatosis.
    Tao XR; Rong JB; Lu HS; Daugherty A; Shi P; Ke CL; Zhang ZC; Xu YC; Wang JA
    J Lipid Res; 2019 Dec; 60(12):1983-1995. PubMed ID: 31604805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exogenous galanin alleviates hepatic steatosis by promoting autophagy via the AMPK-mTOR pathway.
    Zhu S; Wang S; Luo T
    Arch Biochem Biophys; 2023 Aug; 744():109689. PubMed ID: 37429535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LB100 ameliorates nonalcoholic fatty liver disease
    Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
    World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COX-2/sEH Dual Inhibitor Alleviates Hepatocyte Senescence in NAFLD Mice by Restoring Autophagy through Sirt1/PI3K/AKT/mTOR.
    Zhang CY; Tan XH; Yang HH; Jin L; Hong JR; Zhou Y; Huang XT
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The S100 calcium-binding protein A11 promotes hepatic steatosis through RAGE-mediated AKT-mTOR signaling.
    Teng F; Jiang J; Zhang J; Yuan Y; Li K; Zhou B; Zhou X; Liu W; Zhang P; Liu D; Zheng M; Lu Y; Zhang H
    Metabolism; 2021 Apr; 117():154725. PubMed ID: 33571540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.